# Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

> **NCT02877927** · PHASE3 · COMPLETED · sponsor: **Paratek Pharmaceuticals Inc** · enrollment: 735 (actual)

## Conditions studied

- Bacterial Infections
- Skin Structures and Soft Tissue Infections

## Interventions

- **DRUG:** Omadacycline
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT02877927
- **Lead sponsor:** Paratek Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-05-26
- **Final completion:** 2017-06-06
- **Target enrollment:** 735 (ACTUAL)
- **Last updated:** 2018-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02877927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02877927, "Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02877927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*